ReviewPharmacoEconomics2008
Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.
Review in PharmacoEconomics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Regional variations in excessive polypharmacy and potentially inappropriate drug use among older adults in Sweden: Trends from 2006 to 2020.Frontiers in pharmacology · 2023Article
- Forecasting drug utilization and expenditure: ten years of experience in Stockholm.BMC health services research · 2020Article
- Influence of generic reference pricing on medicine cost in Slovenia: a retrospective study.Croatian medical journal · 2018Article
- The Early Awareness and Alert System in Sweden: History and Current Status.Frontiers in pharmacology · 2017Review
- The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2014Review
- Market access of cancer drugs in European countries: improving resource allocation.Targeted oncology · 2014Review
- Patient perceptions of generic medicines: a mixed-methods study.The patient · 2014Article
- Personalizing health care: feasibility and future implications.BMC medicine · 2013Review
- Differences in drug utilisation between men and women: a cross-sectional analysis of all dispensed drugs in Sweden.BMJ open · 2013Article
- A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.BMC pharmacology & toxicology · 2013Review
- Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.Frontiers in pharmacology · 2013Article
- International variability in the reimbursement of cancer drugs by publically funded drug programs.Current oncology (Toronto, Ont.) · 2012Article
- Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.Frontiers in pharmacology · 2012Article
- GPs' opinions of public and industrial information regarding drugs: a cross-sectional study.BMC health services research · 2011Article
- Use of economic evaluation in decision making: evidence and recommendations for improvement.Drugs · 2010Article
- Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?Pharmaceuticals (Basel, Switzerland) · 2010Review
- Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.BMC health services research · 2010Review
- Regional variation and adherence to guidelines for drug treatment of asthma.European journal of clinical pharmacology · 2010Article
- How to assess the value of medicines?Frontiers in pharmacology · 2010Article
- Policies to enhance prescribing efficiency in europe: findings and future implications.Frontiers in pharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With an aging population and increased prevalence of chronic diseases, such as obesity and diabetes mellitus, drug reforms are needed across Europe to ensure the continued provision of comprehensive healthcare. It is also a challenge, with the limited resources available, to fund new innovative drugs that significantly improve patient health. Recent national and regional reforms in Sweden have moderated the rate of increase in drug expenditure, despite increased volumes of drug use and the launch of new, expensive drugs. National reforms include the adoption of economic principles when assessing the value and subsequent reimbursement of new and existing drugs, as well as reforms to obtain low prices for generic drugs. Regional reforms aim to encourage the rational use of medicines through the establishment of drug and therapeutic committees, development of guidelines, academic detailing, continuous benchmarking of prescribing patterns, and financial incentives. Some of these reforms provide examples to other European countries, whilst others duplicate existing measures. As such, we believe other European countries can benefit from an analysis of the Swedish reforms. We believe the pharmaceutical industry can also benefit from this analysis by working with key regional payers involved with developing and implementing the reforms as they moderate and refine their future activities, including finding acceptable ways of introducing new expensive drugs.
Indexed as
Identifiers
18563945What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.